Congenital cataract: a guide to genetic and clinical management

Suzannah J. Bell, Ngozi Oluonye, Philippa Harding and Mariya Moosajee

Abstract: Worldwide 20,000–40,000 children with congenital or childhood cataract are born every year with varying degrees and patterns of lens opacification with a broad aetiology. In most cases of bilateral cataract, a causative genetic mutation can be identified, with autosomal dominant inheritance being most common in 44% of cases. Variants in genes involve lens-specific proteins or those that regulate eye development, thus giving rise to other associated ocular abnormalities. Approximately 15% of cases have systemic features, hence paediatric input is essential to minimise comorbidities and support overall development of children at high risk of visual impairment. In some metabolic conditions, congenital cataract may be the presenting sign, and therefore prompt diagnosis is important where there is an available treatment. Multidisciplinary management of children is essential, including ophthalmic surgeons, orthoptists, paediatricians, geneticists and genetic counsellors, and should extend beyond the medical team to include school and local paediatric visual support services. Early surgery and close follow up in ophthalmology is important to optimise visual potential and prevent amblyopia. Routine genetic testing is essential for the complete clinical management of patients, with next-generation sequencing of 115 genes shown to expedite molecular diagnosis, streamline care pathways and inform genetic counselling and reproductive options for the future.

Keywords: cataract, congenital cataract, genetics, inherited cataract, paediatric ophthalmology

Received: 10 April 2020; revised manuscript accepted: 5 June 2020.

Lay title
Childhood cataract: how to manage patients

Lay abstract
Cataract is a clouding of the lens in the eye. Cataract occurring in children has many different causes, which may include infections passed from mother to child during pregnancy, trauma, medications and exposure to radiation. In most cases of cataract occurring in both eyes, a genetic cause can be found which may be inherited from parents or occur sporadically in the developing baby itself while in the womb. Cataracts may occur on their own, with other eye conditions or be present with other disorders in the body as part of a syndrome. Genetic testing is important for all children with cataract as it can provide valuable information about cause, inheritance and risk to further children and signpost any other features of the disease in the rest of the body, permitting the assembly of the correct multidisciplinary care team. Genetic testing currently involves screening for mutations in 115 genes already known to cause cataract and has been shown to expedite diagnosis and help better manage children. Genetic counselling...
services can support families in understanding their diagnosis and inform future family planning. In order to optimise vision, early surgery for cataract in children is important. This is because the brain is still developing and an unobstructed pathway for light to reach the back of the eye is required for normal visual development. Any obstruction (such as cataract) if left untreated may lead to permanent sight impairment or blindness, even if it is removed later. A multidisciplinary team involved in the care of a child with cataract should include ophthalmic surgeons, orthoptists, paediatricians, geneticists and genetic counsellors, and should extend beyond the medical team to include school and local child visual support services. They will help to diagnose and manage systemic conditions, optimise vision potential and help patients and their families access best supportive care.

Introduction
Worldwide, 20,000–40,000 children with congenital or childhood cataract are born every year, and there are an estimated 200,000 children blind from bilateral cataract.1 In the UK, childhood cataract affects 2.5–3.5 per 10,000 children, with most occurring within the first year of life.2 Genetic mutations account for the majority of cases of bilateral cataract, and the most frequent mode of inheritance is autosomal dominant seen in 44% of families.3 Important environmental factors to consider include congenital infections such as toxoplasma, syphilis, varicella zoster, parvovirus B19, coxsackievirus, rubella, cytomegalovirus (CMV) and herpes simplex virus I and II (TORCH). Trauma and iatrogenic causes such as medications and radiation exposure are also relevant but rare in this age group. Inherited congenital cataract may occur in isolation (70%), with other ocular abnormalities (complex) (15%) or form part of a syndrome (15%).4 Because a wide range of conditions is associated with congenital cataract, often many investigations are performed to identify an underlying cause. There is variability in the investigative pathways of paediatric cataract patients, with some not undergoing any testing despite a family history, or inappropriate and inefficient use of screening tests.5 Implementation of genetic testing using next-generation sequencing has provided evidence of streamlining this process.6

Surgery for paediatric cataract has many considerations and early interdisciplinary management is important for good long-term visual outcomes. General paediatric involvement is essential to aid diagnosis and management of children presenting with systemic features and in the management of vision in the developing child as well as supporting families in challenges that may present throughout childhood. There is often significant responsibility placed on parents who have a critical role in adherence to intensive treatment – for example, with patching or frequent administration of eye drops post-operatively and multiple hospital visits.

Aetiology and classification
The human lens is formed in utero from surface ectodermal cells, which thicken to form the lens placode and then invaginate and pinch off to form the lens vesicle by day 33 of gestation.7,8 The posterior epithelial cells elongate anteriorly to occlude the lumen of the vesicle and form the primary lens fibres. Only the anterior epithelial cells at the equatorial regions of the lens divide to form secondary lens fibres, and this continues throughout life (Figure 1).9

Cataract develops due to disruption of the normal lens protein structure or function, resulting in opacity. This may occur as a result of stressors applied to lens proteins including those acquired in utero or during childhood. However, a significant proportion is due to mutations in the genes encoding lens proteins that directly affect their role within the lens.8 Various congenital cataract morphology have been described, including nuclear, posterior/anterior polar, pulverulent lamellar, posterior subcapsular, cerulean or blue dot cataract (Figure 2).

Cataract can be categorised according to age of presentation. True congenital cataract presents at birth, while cataract that develops later in childhood is described in various ways (e.g. developmental, infantile, juvenile) with different criteria for
inclusion in these classifications.\textsuperscript{10–12} Categorisation in this way can be challenging, as cataract may exist at birth but not be identified until later, which is important in countries where delayed presentation is an issue.\textsuperscript{13}

\textit{Inherited cataract}

The proportion of cataract due to genetic mutations is likely higher than we think because many patients are not tested and there are more cataract causing genes to be discovered. It is possible to identify a genetic mutation in up to 90\% of cases of bilateral cataract with current genetic testing.\textsuperscript{3}

There is substantial genetic and phenotypic heterogeneity with significant intra- and inter-familial variability. Mutations in genes encoding lens proteins can also demonstrate pleiotropic effects – for example, \textit{NHS} gene, which causes Nance–Horan syndrome has a complex pattern of temporally and spatially regulated gene expression involving the development of ocular, craniofacial and neural tissue.\textsuperscript{14,15} For some cataract-associated genes, the resulting phenotype can vary widely depending on the localisation of the respective nucleotide change. The \textit{LSS} gene encodes lanosterol synthase, which is an enzyme involved in the biosynthesis of cholesterol in the

\textbf{Figure 1.} The stages of human lens development. [a] The preplacodal region develops within the surface ectoderm overlying the optic pit/groove. [b] Signalling from the optic vesicle stimulates the preplacodal region to thicken to form the lens placode. [c] Cell proliferation at the lens placode, in addition to morphological changes including apical constriction, result in the formation of a lens pit. [d] Detachment of the lens vesicle from the surface ectoderm, which is rebuilt to later form the corneal epithelium. [e] Posterior epithelial cells elongate anteriorly to occlude the lumen of the lens vesicle. Maturation of the cornea into the epithelium, stroma and endothelium. [f] Epithelial cells at the equatorial regions form secondary lens fibre cells, which elongate anteriorly and posteriorly, encircling the primary lens fibres.
body. Romano et al. suggested that autosomal recessive mutations occurring towards the N-terminus of this gene are associated with hair loss and those at the C-terminus are associated with lens defects. This theory is consolidated by Chen et al., who reported a mixed phenotype in an individual with baldness, absent eyebrows and congenital cataracts with two heterozygous mutations occurring in \( LSS \) c.1025T\( > \)G, p.(Ile342Ser) and c.1887G\( > \)T, p.(Trp629Cys) near the N- and C-terminal regions respectively.

**Non-syndromic congenital cataract.** The main lens proteins associated with congenital cataract include crystallins, membrane proteins, cytoskeletal structural proteins and transcription factors. Some of these genes are also involved in the development of other ocular structures; hence in approximately 15% of cases mutations can lead to associated eye abnormalities.

**Crystallins.** \( \alpha \), \( \beta \) and \( \gamma \)-crystallins are the main structural refractive protein of the human lens; thus mutations in this family of genes result in opacity. In addition, \( \alpha \)-crystallins behave like molecular chaperones, where they assist in the folding or unfolding of other damaged or denatured proteins such as \( \beta \) and \( \gamma \)-crystallins, and can inhibit apoptosis. These functions are critical for maintaining lens transparency. Approximately 50% of non-syndromic hereditary cataract are due to mutations in genes coding for crystallin proteins with over 100 mutations, mostly missense, encoding 12 different human \( \alpha \), \( \beta \) and \( \gamma \)-crystallin genes (Table 1).

**Cytoskeletal structural proteins.** Beaded filament structural proteins (BFSPs) are a type of intermediate filament protein that are expressed in various cells of the body, such as epithelial, glial and muscle cells. \( BFSP1 \) and \( BFSP2 \) are genes encoding Filensin and Phakinin, respectively, which are proteins expressed exclusively in the lens. They are intimately associated with crystallins, where they form part of a highly organised cytoskeleton and are also thought to have an important role in lens development and differentiation. Autosomal recessive \( BFSP2 \) mutations...
**Table 1.** Genes associated with isolated cataract. Detailed phenotype data sourced from Genomics England PanelApp and OMIM cataract databases and associated relevant publications.

| Gene name/locus | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Phenotype |
|-----------------|------------------------|-------------|--------------------|--------------|-----------|
| **AGK**         | 610345                 | AR          | 614691             | Cataract 38, congenital cataract | Congenital cataract |
| **BFSP1**       | 603307                 | AD/AR       | 611391             | Cataract 33, multiple types | Cortical, nuclear, punctate lamellar cataracts |
| **BFSP2**       | 603212                 | AD          | 611597             | Cataract 12, multiple types | Lamellar, cortical, nuclear embryonic, ‘scattered lens opacities’ |
| **CHMP4B**      | 610897                 | AD          | 605387             | Cataract 31, multiple types | Posterior subcapsular cataract, progressing to affect nucleus and anterior subcapsular regions. Posterior polar cataracts |
| **CRYAA**       | 123580                 | AD/AR       | 604219             | Congenital cataract; cataract 9, multiple types | Nuclear, zonular, central nuclear, laminar, lamellar, anterior polar, posterior polar, cortical, embryonal, anterior subcapsular, fan-shaped, total cataracts |
| **CRYAB**       | 123590                 | AD/AR       | 613763             | Cataract 16, multiple types | Nuclear, posterior polar, nuclear, lamellar cataracts |
| **CRYBA1**      | 123610                 | AD          | 600881             | Cataract 10, multiple types; cataract congenital zonular with sutural opacities | Cataract 10, cataract congenital zonular with sutural opacities, nuclear, lamellar cataract |
| **CRYBA2**      | 600836                 | AD          | 115900             | Cataract 42 | Multifocal cataract, congenital, juvenile, posterior polar, early cataract |
| **CRYBA4**      | 123631                 | AD          | 610425             | Cataract 23 | Lamellar and nuclear cataracts |
| **CRYBB1**      | 600929                 | AD/AR       | 611544             | Congenital nuclear cataract; cataract 17, multiple types | Congenital nuclear cataract, pulverulent cataracts |
| **CRYBB2**      | 123620                 | AD          | 601547             | Cataract 3, multiple types | Coppock-like cataract, cerulean cataracts |
| **CRYBB3**      | 123630                 | AD/AR       | 609741             | Congenital nuclear cataract; Cataract 22 | Congenital, cortical, nuclear cataract |
| **CRYGB**       | 123670                 | AD          | 615188             | Cataract 39, multiple types | Anterior polar, lamellar cataract |
| **CRYGC**       | 123680                 | AD          | 604307             | Cataract 2, multiple types; AD cataract coppock-like; | Cataract, variable zonular pulverulent, coppock-like cataract |
| **CRYGD**       | 123690                 | AD          | 115700             | Cataracts; cataract 4, multiple types, congenital cerulean cataract | Aculeiform, progressive, congenital cerulean cataract |
| **CRYGS**       | 123730                 | AD          | 116100             | Cataract 20, multiple types | Progressive polymorphic cortical cataract, progressive ‘opalescent’ cataract |
| **CYP51A1**     | 601637                 | AR          | N/A                | Autosomal recessive cataract due to abnormal sterol metabolism | Not otherwise specified, congenital cataract total white cataracts |
| **DNMBP**       | 611282                 | AR          | 618415             | Cataract 48 | Infantile onset cataracts |

(Continued)
Table 1. (Continued)

| Gene name/locus | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Phenotype |
|-----------------|------------------------|-------------|--------------------|--------------|-----------|
| EPHA2           | 176946                 | AD          | 116600             | Age-related cortical cataract; cataract 6, multiple types | Age-related cortical cataract. Persistent foetal vasculature, posterior polar, posterior subcapsular cataracts |
| FOXE3           | 601094                 | AD/AR       | 612968             | Autosomal dominant cataracts; cataract 34, multiple types. | Membranous, posterior subcapsular cataracts |
| FOCO1           | 607182                 | AR          | 610019             | Congenital cataract; cataract 18 | Nuclear cataract, congenital cataracts |
| GJA3            | 121015                 | AD          | 601885             | Zonular pulverulent cataract; cataract 14, multiple types | Nuclear pulverulent, zonular pulverulent cataract posterior polar, nuclear coralliform, embryonal nuclear, coppock-like cataracts |
| GJA8            | 600897                 | AD          | 116200             | Cataract 1, multiple types | Zonular pulverulent, nuclear progressive |
| HSF4            | 602438                 | AD/AR       | 116800             | Cataracts; cataract 5, multiple types | Lamellar, zonular stellate, anterior polar cataracts |
| LEMD2           | 616312                 | AR          | 212500             | Cataract 46, juvenile-onset | Juvenile-onset ‘Hutterite-type cataract’ |
| LIM2            | 154045                 | AR          | 615277             | Cortical pulverulent cataract; Cataract 19 | Cortical pulverulent cataract, congenital total cataract, nuclear cataract |
| LSS             | 600909                 | AR          | 616509             | Cataract 44 | Total cataract |
| MAF             | 177075                 | AD          | 610202             | Cataract, pulverulent or cerulean, without microcornea; cataract 21, multiple types | Cataract, pulverulent or cerulean, without microcornea, cataract 21, cortical pulverulent, nuclear pulverulent with progression to posterior subcapsular cataract. Lamellar, anterior polar, nuclear, anterior subcapsular cataracts |
| MIP             | 154050                 | AD          | 615274             | Cataracts; cataract 15, multiple types | Cataract 15, anterior and posterior polar, cortical cataract, progressive punctate lamellar, non-progressive congenital lamellar and sutural cataracts, embryonal nuclear cataracts |
| NHS             | 300457                 | XD          | 302200             | Cataract 40, X-linked | Total nuclear, sutural, lamellar, zonular, perinuclear, posterior stellate cataracts |
| PITX3           | 602669                 | AD, AR      | 610623             | Cataract 11, multiple types | Cataract 11, posterior polar, total and cortical cataracts |
| TDRD7           | 611258                 | AR          | 613887             | Cataract 36 | Congenital cataracts |
| UNC45B          | 611220                 | AR          | 616279             | Cataract 43 | Posterior subcapsular and central cataracts |
| VIM             | 193060                 | AD          | 116300             | Cataract 30, pulverulent | Pulverulent cataracts |
| WFS1            | 606201                 | AD/AR       | 116400             | Cataract 41 | Congenital nuclear cataract |

AD, Autosomal dominant; AR, autosomal recessive; XD, x-linked dominant.
## Table 2. Genetic mutations associated with cataract and other ocular malformations. Detailed phenotype data sourced from Genomics England PanelApp and OMIM cataract databases and associated relevant publications.

| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Ocular comorbidities (besides cataract) |
|-------------|-----------------------|-------------|-------------------|--------------|---------------------------------------|
| **CRYBA1**  | 123610                | AD          | 600881            | Cataract 10, multiple types | Nystagmus, esotropia                   |
| **CRYBA2**  | 600836                | AD          | 115900            | Cataract 42  | Eccentric pupil, glaucoma, myopia     |
| **CRYBA4**  | 123631                | AD/AR       | 610425            | Cataract 23  | Microcornea, microphthalmia           |
| **CRYBB1**  | 600929                | AD/AR       | 611544            | –            | Microcornea, nystagmus, iris and choroid coloboma |
| **CRYBB2**  | 123620                | AD          | 601547            | Cataract 3, multiple types | Microphalma, microcornea, coloboma (posterior segment), glaucoma |
| **CRYGC**   | 123680                | AD          | 604307            | Cataract 2, multiple types; AD cataract coppock-like | Microcornea |
| **CRYGD**   | 123690                | AD          | 115700            | Cataract 4, multiple types | Microcornea |
| **DNMBP**   | 611282                | AR          | 618415            | Cataract 48  | Nystagmus, amblyopia, exotropia       |
| **EPHA2**   | 176946                | AD          | 116600            | Cataract 6, multiple types | Microcornea |
| **FOXE3**   | 601094                | AD/AR       | 610256            | Peters anomaly | ASD,ocular dysgenesis, corneal opacity, Peters anomaly, microphalma, microcornea, nystagmus |
| **GJA3**    | 121015                | AD          | 601885            | Cataract 14, multiple types | Microphalma, microcornea |
| **GJA8**    | 600897                | AD          | 116200            | Cataract-microcornea syndrome | Microcornea, microphalma, glaucoma, ASD, coloboma, sclerocornea, total corneal opacification |
| **MAF**     | 177075                | AD          | 610202            | –            | Microcornea, iris coloboma, microcornea, glaucoma, microphalma, myopia, nystagmus, Peters anomaly |
| **NHS**     | 300457                | XD          | 302200            | Cataract 40, X-linked | Microcornea, microphalma |
| **OPA3**    | 258501                | AD          | 258501            | Autosomal dominant optic atrophy with cataract (ADOAC) | Optic atrophy |
| **P3H2**    | 610341                | AR          | 614292            | –            | High myopia, lens dislocation, retinal detachment, vitreoretinal degeneration |
| **PAX6**    | 607108                | AD          | 106210            | –            | Cataract with late-onset corneal dystrophy |
| **PITX3**   | 602669                | AD          | 610623            | –            | Anterior segment dysgenesis |
| **PXDN**    | 605158                | AR          | 269400            | –            | Corneal opacity, developmental glaucoma; corneal opacification associated with other ocular anomalies (COPA) |
| **VSX2**    | 142993                | AR          | 610092            | –            | Microphalma and iris abnormalities. Microphalma with coloboma type 3, microphalma isolated type 2 |

AD, Autosomal dominant; AR, autosomal recessive; XD, x-linked dominant; ASD, anterior segment dysgenesis.
cause cataract, but interestingly it has been suggested that heterozygous carriers of these mutations may be predisposed to develop age-related cataract and myopia (Table 2).20

Membrane proteins. The lens is an avascular structure and therefore membrane proteins have an important role in maintenance and metabolic homeostasis. Genetic mutations in over 10 membrane protein genes lead to inappropriate transport of ions, solutes and water between cells in the human lens (Table 1). Gap junction channels are made up of two connexons composed of six subunits called connexins.21 Connexins have an important role in lens microcirculation, particularly in the supply of metabolites and nutrients towards the centre of the lens, and outward flow of unwanted ions and by-products to the periphery.22 They are able to form functional hemichannels in a variety of species. Three particular cataract-causing mutations result in increased hemichannel activity: GJA3 (encoding human lens connexin 46) c.427G>A, p.(Gly143Arg) and c.56C>T, p.(Thr19Met), and GJA8 (encoding connexin 50) c.137G>T, p. (Gly46Val). Two mutations in GJA8 c.827C,T, p.(Ser276Phe) and c.131T>C, p.(Val44Ala) decrease hemichannel activity and have also been implicated in the formation of cataract.23 Mutations in these genes are most commonly associated with zonular and nuclear pulverulent cataracts with varying progression.23–25 These mutations are most frequently missense, and GJA8 is also associated with microcornea.26,27

Mutations in genes encoding major intrinsic proteins account for 5% of all inherited cataract.28 Aquaporin-0 is the most expressed membrane protein in the human lens and variants are inherited in an autosomal dominant pattern producing a variety of cataract phenotypes (Table 1).29,30 It functions primarily as a water channel, but recent research in mouse models suggests that it may also modulate gap junctions in the presence of BFSPs.31 Lens intrinsic membrane protein-2 (LIM2) is the gene responsible for a membrane protein with four transmembrane domains called MP19, which contribute to lens transparency.32–34 Three LIM2 missense mutations have been described that cause autosomal recessive cataract (1) c.313T>G, p.(Phe105Val) mutation associated with cortical cataract; (2) c.587G>A, p.(Gly154Glu) mutation in a family causing autosomal recessive cataract; and (3) c.233G>A, p.(Gly78Asp) mutation in a consanguineous Pakistani family with nuclear cataracts.35,36

Other proteins working at the membrane include EPHA2 and DNMBP. EPHA2 encodes a membrane-bound protein tyrosine kinase,37 and mutations have been shown to account for approximately 5% of inherited cataracts in the Australian population.38 Most known causative mutations occur in the sterile-α-motif region of the molecule that affects the structure of the EPHA2 protein and impairs cell migration in human and mouse fibroblast lens epithelial cells.39 Mislocalisation of two mutant proteins away from the cell membrane has also been implicated in cataractogenesis.37 EPHA2 mutations are most often associated with autosomal dominant posterior polar cataract. DNMBP encodes a protein that regulates the configurations of cell junctions through binding to tight junction protein 1. Biallelic loss-of-function variants have been shown to result in autosomal recessive cataract with other ocular features, including pupil abnormalities, strabismus and nystagmus.40

Transcription factors. Heat shock transcription factor 4 (HSF4) protects lens proteins from cell stressors and has a regulatory role in the differentiation of lens fibre cells.41 Mutations in HSF4 most often produce lamellar cataract, which can be present at birth or develop in early childhood, and can be inherited in a dominant or recessive mode. Of the 16 mutations described so far, 13 are missense and 11 occur in the protein’s DNA binding domain; these are autosomal dominant, suggesting this region is essential for normal protein function.42

Similarly, MAF encodes a transcription factor containing the basic-leucine zipper (bZIP) domain in which 7 of the 18 known mutations are associated with ocular defects such as iris coloboma, glaucoma, microcornea, microphthalmia, myopia, nystagmus and Peters anomaly.42 This suggests the bZIP domain has a critical role in eye development. Mutations in the N-terminal upstream of a transactivation domain encoding region of the MAF gene are associated with Ayme-Gripp syndrome (cataract, reduced growth, sensorineural hearing loss, learning disability, brachycephaly and seizures) and Asperger syndrome (Table 3).42

journals.sagepub.com/home/trd
Table 3. Genetic mutations associated with syndromic cataract. Detailed phenotype data from Genomics England PanelApp and OMIM cataract databases and associated relevant publications.

| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|------------------------|-------------|--------------------|--------------|-----------------------------------|
| ADAMTS10    | 608990 AR              |             | 277600             | Weill–Marchesani syndrome | Short stature, brachycephaly, joint stiffness |
| AGK         | 610345 AR              |             | 212350             | Sengers syndrome | Hypertrophic cardiomyopathy, skeletal myopathy, exercise intolerance |
| AGPS        | 603051 AR              |             | 600121             | Rhizomelic chondrodysplasia punctata type 3 | Short stature, broad nasal bridge, epicanthus, high-arched palate, dysplastic external ears, micrognathia, congenital contractures, dwarfism, severe mental disability with spasticity |
| ALDH18A1    | 138250 AD/AR           |             | 616603             | Autosomal dominant/recessive cutis laxa-3 (ADCL3/ARCL3) | Mental disability, joint hypermobility, skin hyperelasticity, metabolic abnormalities: hyperammonemia/prolinemia/ornithinemia |
| B3GLCT      | 610308 AR              |             | 261540             | Peters-plus syndrome | Peters anomaly, growth retardation, short stature, brachydactyly, developmental delay |
| BCOR        | 300166 XD              |             | 300485             | Oculofaciocardiodental syndrome | Eye anomalies (microphthalmia, glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose, cleft palate), cardiac anomalies (atrial/ventricular septal defect, floppy mitral valve), dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, etc.). |
| COL2A1      | 120140 AD              |             | 609508             | Stickler syndrome type I non-syndromic ocular | Congenital vitreous abnormality (vestigial gel in retrolental space) with midline clefting, flat midface, hearing loss, mild spondyloepiphyseal dysplasia, early onset arthritis |
| COL4A1      | 120130 AD              |             | 175780             | –              | Brain small vessel disease with or without ocular anomalies; microphthalmia |
| COL4A5      | 303630 XD              |             | 301050             | Alport syndrome | Progressive renal failure, hearing loss and lenticous, corneal erosions, retinal flecks |
| COL11A1     | 120280 AD              |             | 154780             | Marshall syndrome; Stickler syndrome | Hearing loss, retinal detachment, midfacial hypoplasia, palatal hypoplasia |
| COL18A1     | 120328 AR              |             | 267750             | Knobloch syndrome | High myopia, vitreo-retinal degeneration, retinal detachment |
| CRYAB       | 123590 AD/AR           |             | 613763             | –              | Myofibrillar myopathy, adult onset cardiomyopathy, dilated cardiomyopathy |

(Continued)
| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|-----------------------|-------------|-------------------|--------------|---------------------------------------|
| **CYP27A1** | 606530                | AR          | 213700            | Cerebrotendinous xanthomatosis | Childhood cholestasis, tendon xanthomas. Neurological complications in adulthood including neuropsychiatric disturbance, increased muscle tone, ataxia, dystonia, seizures |
| **CYP51A1** | 601637                | AR          | –                 | –            | Developmental delay, spastic diplegia, and cryptogenic neonatal liver cirrhosis, neonatal cholestatic jaundice |
| **DCR**     | –                     | IC          | 190685            | Down’s syndrome | Mental disability, characteristic facies, cardiac anomalies, gastrointestinal tract disorders, leukaemia, hearing loss, early Alzheimer's disease |
| **DHCR7**   | 602858                | AR          | 270400            | Smith–Lemli–Opitz syndrome | Hypotonia, microcephaly, micrognathia, craniofacial abnormalities, postaxial polydactyly, syndactyly, hypospadias, developmental delay |
| **DMPK**    | 605377                | AD          | 160900            | Myotonic dystrophy 1 | Myotonia muscular dystrophy, cataracts, hypogonadism, frontal balding, ECG changes |
| **EED**     | 605984                | AD          | 617561            | Cohen–Gibson syndrome | Dysmorphic facial features, advanced bone age, skeletal anomalies, large hands, long fingers and camptodactyly, scoliosis and cervical spinal abnormalities |
| **EIF2B2**  | 606454                | AR          | 603896            | Leukoencephalopathy with vanishing white matter | Variable neurological features, including progressive cerebellar ataxia, spasticity, cognitive impairment associated with white matter lesions on brain imaging |
| **EPHA2**   | 176946                | AD          | 116600            | –              | Microcornea, phacodenesis, neurodevelopmental delay, mild dysmorphic features |
| **ERCC2**   | 126340                | AR          | 610756            | Cerebrooculofacioskeletal syndrome [COFS2]; trichothiodystrophy 1 [TTD1] | COFS2: microcephaly, prominent nose, microphthalmia, blepharophimosis, large ears, overlapping upper lip, long philtrum, micrognathia. TTD1: brittle sulphur-deficient hair, cutaneous, neurologic and growth abnormalities |
| **ERCC3**   | 133510                | AR          | 616390            | Trichothiodystrophy 2 [TTD2] | Brittle sulphur-deficient hair, cutaneous, neurologic and growth abnormalities |

(Continued)
Table 3  (Continued)

| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|-----------------------|-------------|--------------------|--------------|---------------------------------------|
| ERCC6       | 609413                | AR          | 133540             | Cockayne syndrome type B(CSB); cerebrooculofacioskeletal syndrome 1(COFS1) | CSB: progeroid appearance, cachectic dwarfism, failure to thrive, mental disability, loss of adipose tissue, joint contractures, sensorineural hearing loss. COFS1: microcephaly, mental disability, facial dysmorphism, arthrogryposis |
| ERCC8       | 609412                | AR          | 216400             | Cockayne syndrome type A MIMID | Progeroid appearance, cachectic dwarfism, mental disability, loss of adipose tissue, sensorineural hearing loss. |
| FAM126A     | 610531                | AR          | 610532             | Leukodystrophy hypomyelinating 5 | Hypomyelination resulting in psychomotor regression, mental disability, sensorimotor peripheral neuropathy |
| FBN1        |                       | AD          |                    | Marfan syndrome | Skeletal, ocular and cardiovascular abnormalities. Long limbs and fingers, high-arched palate, aortic dilatation/regurgitation, myopia, subluxation of lens |
| FOXE3       | 601094                | AD          | 612968             | Cataract 34, multiple types | Vitreoretinal dysplasia, neurodevelopmental delay, joint laxity |
| FTL         | 134790                | AD          | 600886             | Hyperferritinemia-cataract syndrome | Hyperferritinemia, microcytic anaemia |
| GALK1       | 604313                | AR          | 230200             | Galactokinase deficiency with cataracts | Elevated plasma galactose with milder features of galactosaemia |
| GALT        | 606999                | AR          | 230400             | Galactosemia | Elevated plasma galactose with poor feeding with poor weight gain, vomiting and diarrhoea, liver cell damage and lethargy |
| GCNT2       | 600429                | AR          | 116700             | Adult i blood group with congenital cataract | Adult i blood group |
| GEMIN4      | 606969                | AR          | 617913             | – | Neurodevelopmental disorder with microcephaly, renal abnormalities |
| GNPAT       | 602744                | AR          | 222765             | Rhizomelic chondrodysplasia punctata type 2 | Rhizomelic skeletal dysplasia, mental disability |
| GTF2H5      | 608780                | AR          | 616395             | Trichoiodystrophy 3, photosensitive | Brittle sulphur-deficient hair, cutaneous, neurologic and growth abnormalities |
| HMX1        | 142992                | AR          | 612109             | Oculoauricular syndrome | Microphthalmia, microcornea, corneal opacity, coloboma, external ear abnormalities |

(Continued)
| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|-----------------------|-------------|-------------------|--------------|---------------------------------------|
| HTRA2       | 606441                | AR          | 617248            | 3-methylglutaconic aciduria, type VIII | Death in infancy. Hypotonia, abnormal movements, respiratory insufficiency, lack of development with seizures |
| INPP5K      | 607875                | AR          | 617404            | Congenital muscular dystrophy with cataracts and mild cognitive impairment (MDCCAID) | Muscular dystrophy with progressive muscle weakness in childhood and mild cognitive impairment |
| JAM3        | 606871                | AR          | 613730            | –             | Haemorrhagic destruction of the brain, subependymal calcification |
| LONP1       | 605490                | AR          | 600373            | CODAS syndrome (cerebral, ocular, dental, auricular, skeletal) | Developmental delay, craniofacial abnormalities, ptosis, median nasal groove, delayed tooth eruption, anomalous cusp morphology, malformed helices, hearing loss, short stature, delayed epiphyseal ossification, metaphyseal hip dysplasia, vertebral coronal clefts |
| LSS         | 616509                | AR          | 600909            | –             | Congenital cataract, hypotrichosis. |
| MAF         | 177075                | AD          | 610202            | Ayme-Gripp syndrome | Sensorineural hearing loss, intellectual disability, seizures, brachycephaly, a distinctive flat facial appearance and reduced growth |
| MAN2B1      | 609458                | AR          | 248500            | Mannosidosis alpha types I and II | Progressive mental disability, immune deficiency, impaired hearing and Hurler-like skeletal changes |
| MSMO1       | 607545                | AR          | 616834            | –             | Microcephaly, psoriasiform dermatitis |
| MYH9        | 160775                | AD          | 155100            | Epstein syndrome; Fechtner syndrome | Nephritis, mild hearing loss, thrombocytopenia |
| NDP         | 300658                | XR          | 310600            | Norrie disease | Very early childhood blindness due to degenerative and proliferative changes of the neuroretina with or without progressive mental disability and psychosis and deafness |
| NF2         | 607379                | AD          | 101000            | Neurofibromatosis type 2 | Multiple neoplasia syndrome. Tumours of either cranial nerve (usually bilateral), meningiomas and schwannomas |
| NHS         | 300457                | XD          | 302200            | Nance–Horan syndrome | Microcornea, dental anomalies for example, Hutchinsonian incisors, mesiodens, dysmorphic features for example, large antverted pinna, mental disability |
| OCRL        | 300535                | XR          | 309000            | Lowe syndrome | Hydrophthalmia, mental disability, vitamin D-resistant rickets, amino aciduria, reduced ammonia produced by kidney |

(Continued)
| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|-----------------------|-------------|-------------------|--------------|--------------------------------------|
| PEX1        | 602136                | AR          | 214100            | Peroxisome biogenesis disorder 1A [Zellweger] (ZS) Refsum disease infantile; Adrenoleukodystrophy neonatal | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy. Symptoms similar to ZS with survival to early childhood. Symptoms similar to ZS with longest survival 3–11 years of age |
| PEX2        | 170993                | AR          | 614866            | Peroxisome biogenesis disorder 5A [Zellweger] | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX3        | 603164                | AR          | 614882            | Peroxisome biogenesis disorder 10A [Zellweger] | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX5        | 600414                | AR          | 214110/202370/616716 | Peroxisome biogenesis disorder 2A [Zellweger] Peroxisome biogenesis disorder 2B Rhizomelic chondrodysplasia punctata, type 5 | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy. Rhizomelic skeletal dysplasia, mental disability |
| PEX6        | 601498                | AR          | 614862            | Peroxisome biogenesis disorder 4A [Zellweger] | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX7        | 601757                | AR          | 215100            | Rhizomelic chondrodysplasia punctata type 1; Refsum disease; peroxisome biogenesis disorder | Rhizomelic skeletal dysplasia, mental disability. Symptoms similar to ZS with survival to early childhood. Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX10       | 602859                | AR          | 614870            | Peroxisome biogenesis disorder 6A [Zellweger]; adrenoleukodystrophy neonatal | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy. Symptoms similar to ZS with longest survival 3–11 years of age |
| PEX11B      | 603867                | AR          | 614920            | Peroxisome biogenesis disorder | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX12       | 614859                | AR          | 614859            | Peroxisome biogenesis disorder 3A [Zellweger]; peroxisome biogenesis disorder complementation group 3 | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX13       | 601789                | AR          | 614883            | Peroxisome biogenesis disorder 11A [Zellweger]; adrenoleukodystrophy neonatal | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy. Symptoms similar to ZS with longest survival 3–11 years of age |

(Continued)
| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|----------------------|-------------|-------------------|--------------|---------------------------------------|
| PEX14 | 601791 | AR | 614887 | Peroxisome biogenesis disorder 13A | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX16 | 603360 | AR | 614876 | Peroxisome biogenesis disorder 8A (Zellweger); Refsum disease infantile; adrenoleukodystrophy neonatal | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX19 | 600279 | AR | 614886 | Peroxisome biogenesis disorder 12A (Zellweger) | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy |
| PEX26 | 608666 | AR | 614872 | Peroxisome biogenesis disorder 7A (Zellweger) [ZS]; Refsum disease infantile; adrenoleukodystrophy neonatal; | Neurological abnormalities, characteristic dysmorphism and hepatomegaly, death in infancy. Symptoms similar to ZS with survival to early childhood. Symptoms similar to ZS with longest survival 3–11 years of age |
| PITX3 | 602669 | AD, AR | 610623 | – | Mental disability, choreiform movements, increased muscle tone, deep tendon reflexes of lower extremities |
| POMT1 | 607423 | AR | 236670 | Walker–Warburg syndrome | Cobblestone (type II) lissencephaly, cerebellar malformations, retinal malformations |
| RAB18 | 602207 | AR | 614222 | Warburg micro syndrome 3 | Congenital microcephaly, cortical dysplasia, microcornea, optic atrophy, severe mental disability, hypotonic diplegia, hypogenitalism |
| RAB3GAP1 | 602536 | AR | 600118 | Warburg micro syndrome 1 | Congenital microcephaly, cortical dysplasia, microcornea, optic atrophy, severe mental disability, hypotonic diplegia, hypogenitalism |
| RAB3GAP2 | 609275 | AR | 212720 | Warburg micro syndrome 2 (WMS2); Martsolf syndrome | Congenital microcephaly, cortical dysplasia, microcornea, optic atrophy, severe mental disability, hypotonic diplegia, hypogenitalism. Milder phenotype of WMS2. Microphthalmia, postnatal microcephaly, developmental delay |
| RECQL4 | 603780 | AR | 268400 | Rothmund–Thompson syndrome, type 2 | Poikilodermat, congenital bone defects, increased risk of osteosarcoma in childhood, skin cancer in adulthood |
| SC5D | 602286 | AR | 607330 | Lathosterolosis | Facial dysmorphisms, severe microcephaly, micrognathia, neonatal jaundice, mental disability, hexadactyly, syndactyly, liver disease |
| SEC23A | 610511 | AR | 607812 | Craniolenticulosutural dysplasia | Facial dysmorphism, late closing fontanelle, skeletal defects |
**Table 3.** (Continued)

| Gene symbol | Gene/locus MIM number | Inheritance | Disease MIM number | Disease name | Frequent associated systemic features |
|-------------|-----------------------|-------------|-------------------|-------------|---------------------------------------|
| SIL1        | 608005                | AR          | 248800            | Marinesco–Sjogren syndrome | Cerebellar ataxia, progressive myopathy |
| SLC2A1      | 138140                | AD          | 608885            | Stomatin-deficient cryohydrocytosis with neurologic defects | Delayed psychomotor development, seizures, pseudohyperkalaemia |
| SLC33A1     | 603690                | AR          | 614482            | –            | Congenital cataracts, hearing loss, and neurodegeneration |
| SRD5A3      | 611715                | AR          | 612713            | Kahrizi syndrome | Mental disability, coloboma, kyphosis |
| TFAP2A      | 107580                | AD          | 113620            | Branchiooculofacial syndrome | High-arched palate, prominent philtrum, narrow ear canals, abnormal pinnae, periorbital and scalp cysts |
| WRN         | 604611                | AR          | 277700            | Werner syndrome | Accelerated ageing appearance and disorders associated with aging including diabetes mellitus, osteoporosis, premature atherosclerosis, benign and malignant neoplasms |
| XYL T2      | 608125                | AR          | 605822            | Spondyloocular syndrome | Bone fragility, hearing defects, retinal detachment, facial dysmorphism, immobile spine, platyspondyly |

AD, Autosomal dominant; AR, autosomal recessive; XD, x-linked dominant; XR, x-linked recessive; IC, isolated cases.

**FOXE3** is one of a family of genes encoding transcription factors with a ‘forkhead’ DNA binding domain and has a role in lens embryology. Twenty-four unique mutations have been shown to affect various ocular structures, including cornea, iris, lens and retina (Table 2).42 Most mutations are missense and 10 occur in the forkhead DNA binding domain, resulting in defective or non-functional protein. Pituitary homeobox 3 (PITX3) proteins are transcription factors that have been shown to play an important role in controlling lens epithelial cell maintenance and fibre cell differentiation in mice.43 They contain the homeobox and the otp, aristless, rax (OAR) domains; however, surprisingly no cataract-causing mutations have been described in either domain. Mutations in PITX3 genes most often cause posterior polar cataract with or without anterior segment dysgenesis (ASD), but can result in other ocular defects such as corneal opacity, microphthalmia, microcornea, nystagmus and glaucoma.42

**Syndromic congenital cataract.** Syndromic congenital cataract manifests as a result of various types of mutations, including chromosomal abnormalities, loss-of-heterozygosity, mitochondrial disorders, triplet repeat disorders and more complex genetic disorders such as diabetes.35 Cataracts show phenotypic variability and are associated with a myriad of systemic dysmorphic features.44 Chromosomal abnormalities featuring cataract include those with an extra copy of chromosome 21 and 13 causing Down’s syndrome (trisomy 21) and Patau syndrome (trisomy 13) respectively. Children with trisomy 21 are born with characteristic features and are prone to various health problems (Table 3), including ocular abnormalities such as cataract, upslanting palpebral fissures, astigmatism, iris abnormalities, strabismus, lacrimal system obstruction, blepharitis, retinal abnormalities, hypermetropia, amblyopia, nystagmus and myopia.45 Cataract has been
Multiple X-linked disorders demonstrate congenital cataracts (Table 3). Lowe syndrome is X-linked recessive, characterised by a triad of features including dense congenital cataracts, intellectual disability and proximal tubular dysfunction. It is caused by mutations in the OCRL gene that encodes inositol polyphosphate 5-phosphatase OCRL-1 and is involved in a large spectrum of intracellular processes, some of which affect actin stress fibres, polymerisation and distribution, which are likely to be responsible for the clinical phenotype. In the neonatal period, hypotonia and cataracts may be seen but the condition may not be diagnosed until later, when renal dysfunction becomes apparent.

Norrie disease is an X-linked recessive disorder caused by mutations in the NDP gene, which encodes Norrin. There are genotype–phenotype correlations with missense mutations in exon 3 resulting in less severe phenotypes than nonsense mutations. Male children often present in the first few weeks of life with blindness due to bilateral retrolental vascularised masses with normalized eyes. Shallow anterior chamber, iris atrophy, cataracts and corneal opacity are common features, with eyes becoming phthisical over time.

Male children with inherited Nance–Horan syndrome have typical facial dysmorphic features (long face, large ears, prominent nose) as well as dental and ocular abnormalities including cataract and developmental delay (Table 3). Interestingly, female carrier children may demonstrate a milder phenotype with Y-sutural lens opacities with cortical ‘riders’ and milder facial and dental abnormalities. Loss-of-function mutations in the NHS gene result in the syndromic disease; however, translocations such as duplications can cause non-syndromic isolated cataract. It has been suggested that this protein could be involved in the regulation of tight junction proteins or in the regulation of actin remodelling and maintaining cell morphology, but the function of this protein remains unknown.

Myotonic dystrophy 1 is also inherited autosomal dominantly but occurs as a result of a cytosine–thymine–guanine (CTG) repeat disorder and is associated with a variety of ocular signs such as cataract, retinal degeneration, low intraocular pressure, eyelid ptosis, epiphora, corneal lesions, extraocular myotonia and weakness and abnormal central control of eye movement. Cataracts are often non-specific and appear as punctate opacities. Neurofibromatosis type 2 is caused by autosomal dominantly expressed mutations in the NF2 gene. It classically presents in adulthood with bilateral vestibular schwannoma (VS); however, in children it most often presents with small posterior capsular or cortical edge cataracts as well as non-VS neurological signs and subtle skin tumours.

Metabolic disorders are an important differential in the cause of congenital cataract, and these are often inherited in an autosomal recessive pattern. Systemic presentations may be mild with cataract being the initial sign. Zellweger spectrum disorder (ZSD) is an autosomal recessive metabolic peroxisome biogenesis disorder presenting with severe features in childhood that result in early death (Table 3); milder phenotypes include neonatal adrenoleukodystrophy and infantile Refsum disease. It is caused by mutations in PEX genes that encode proteins required for peroxisome biogenesis.

Several rare autosomal recessive conditions are associated with the development of cataract. Rothmund–Thompson syndrome is a rare disorder with only 300 known cases. Two-thirds of cases are caused by a mutation in the RECOL4 gene that is involved in DNA replication and repair, thus leading to widespread changes in skin, connective tissue and bone. There is an increased incidence of cancer in childhood and adolescence, in particular bone malignancies (osteosarcomas) and skin cancers, including squamous and basal cell carcinomas. Cockayne syndrome is a rare autosomal recessive disorder presenting with varying severity. Genetic mutations in ERCC6 or ERCC8 affect the repair of mitochondria and DNA damage – for example, due to environmental stressors such as sunlight leading to photosensitivity. Mutations in the CYP27A1 gene lead to an accumulation of cholesterol and cholestenol in tissues and cause cerebrotendinous xanthomatosis (CTX). Developmental cataract is often an early ocular sign of this condition, along with systemic features such as infantile diarrhoea and tendon xanthomas; however, often a diagnosis of CTX is not made until adulthood.
when patients present with a variety of progressive neurological features. Early recognition and treatment with daily chenodeoxycholic acid can halt or even reverse severe neurological complications and improve prognosis.63 Galactosaemia, a rare inherited disorder of galactose metabolism screened for at birth in the UK, is caused by mutations in genes that encode enzymes of galactose. Galactokinase deficiency and classic galactosaemia are caused by mutations in the genes of galactokinase \((GALK1)\) and galactose-1-phosphate \((GALT)\), respectively (Table 3). Nearly 200 mutations in the \(GALT\) gene have been found and presentation is often severe in the first few weeks of life as infants are exposed to breast/formula milk.64 Accumulation of galactitol in the lens causes a characteristic ‘oil droplet’ cataract. Anterior and posterior subcapsular cataract may also occur.65 Early recognition and initiation of a galactose-free diet can reverse lens clouding and prevent fatal systemic consequences.66 Galactokinase deficiency is seen as a mild form of galactosaemia and paediatric cataract is often the major clinical feature.67

**Acquired causes**

**Congenital infections.** Rubella is the most common congenital infection causing cataract worldwide.68 Maternal rubella infection during pregnancy puts the foetus at risk of developing a clinical rubella syndrome comprising a triad of deafness, cataract and cardiac disease. Rubella infection continues to be a public health problem in countries that do not have adequate national immunisation programmes.69,70 Other infections causing cataract include toxoplasmosis, CMV and herpes simplex (HSV I and II). It is common practice to screen for these infections when investigating the cause of paediatric cataract using the TORCH screen, but many factors can affect the positivity of the test, including maternal antibodies in neonates.71 There is some debate over the use of screening in routine practice and a move towards using specific tests for individual cases based on maternal antenatal history, child comorbidities and vaccination status.72

**Trauma.** Traumatic cataract makes up a significant proportion of childhood cataract.73 It has different considerations in terms of its presentation and management compared to true congenital cataract due to its unilaterality and potential damage to other ocular structures, such as angle recession leading to secondary glaucoma. Surgical management can be more complex but with overall less dense amblyopia and better chance of visual rehabilitation.74 Common objects causing trauma vary globally, with bow and arrows being the most common cause of ocular trauma in India, followed by sticks, stones and thorns, which are more common in East Africa.74,75

Other common causes of cataract in children

**Uveitic cataract and steroid-related cataract.** Anterior uveitis is defined as inflammation of the iris and ciliary body. Juvenile idiopathic arthritis (JIA) associated uveitis is the leading cause of ocular morbidity in paediatric patients with uveitis and is associated with HLAB27 positivity. JIA describes a group of arthridities presenting in childhood, and uveitis is an extra-articular feature present in 11–13% of patients. It is more prevalent in females, those with oligoarthritis and positive antinuclear antibodies. Cataract occurring in the context of anterior uveitis may occur as a result of disease-associated inflammation or the prolonged use of steroids in its management, giving rise to deprivation amblyopia and visual loss.76,77 Most commonly steroids produce a posterior subcapsular cataract, and although the precise mechanism is unknown, glucocorticoids are thought to have an important role in the transcription of genes in lens epithelial cells.78

**Radiation cataract.** Exposure to radiation can cause the development of cataract. Children undergoing radiotherapy for treatment of childhood cancers such as leukaemia, central nervous system tumours, lymphomas, kidney cancer, neuroblastoma, soft tissue and bone sarcomas are therefore at risk of developing cataract. At higher doses of radiation – that is, above 3 Gy – cataract develops more quickly; however, more recent evidence suggests it can occur even at lower doses of radiation of 0.5 Gy, with the likelihood following a linear dose response.1 Doses of radiation cannot easily be reduced in the treatment of cancer, but measures can be taken to protect the eye and lens in high-risk patients, such as accurate radiation dose estimates and shielding.1

Management

**Paediatric cataract surgery**

The management of cataract presenting in children is more complicated than that of adult patients. Primarily the risks of performing early
surgery need to be balanced with facilitating the best possible visual development in children during an amblyogenic period. In children, cataract surgery with or without anterior capsulotomy, posterior capsulotomy and anterior vitrectomy are performed. Intraocular lens (IOL) insertion is another point of contention. Findings from 5-year follow-up studies suggest that for children younger than 2 years old, inserting an IOL often results in similar post-operative vision when compared with contact lens only, it does not protect against post-operative glaucoma and results in additional requirement for intraocular surgery. Therefore, the recommendation is that children are left aphakic, and certainly those less than 6 months of age, until further evidence is presented. Selecting an IOL is difficult as the eye is growing and power calculations are more challenging because of difficulty attaining accurate measurements in the child. It is recommended that cataract should be extracted at 6 weeks of age for unilateral cataract and between 6 and 8 weeks of age in bilateral cataract. Rigorous post-operative care in children and regular follow up are essential for good long-term visual outcomes. Younger children undergoing lensectomy have better visual outcomes but are at higher risk of glaucoma, but conversely children having surgery later are at higher risk of strabismus. Non-surgical management may be appropriate with dilating drops for partial cataracts to increase light entering the eye. In galactosaemia cases, modification of diet and enzyme replacement may cause cataracts to stop progressing or even regress.

**Genetic testing**

Genetic testing is a key investigation for congenital cataracts, and recent studies have shown molecular diagnostic rates between 50% and 90% for bilateral cases. Current practice involves using a targeted gene panel of cataract-related genes using next-generation sequencing technology, which has ≥90% coverage. However, whole-genome sequencing (screening of all coding and non-coding intergenic and intragenic regions) has been estimated to increase diagnostics rates by a further 40%. Genetic testing has been found to expedite diagnosis and provide a personalised clinical management plan, streamlining care pathways for patients, supporting informed genetic counselling and making informed decisions with regards to family planning. Research focuses on integrating this evidence into clinical practice and establishing robust genotype–phenotype correlations to aid prognosis and to ensure systemic features are detected earlier to reduce comorbidities.

**Multidisciplinary care**

Multidisciplinary management is essential to ensure full investigation and appropriate care pathways are established with paediatricians’ input, to exclude metabolic disorders, congenital infections and other syndromic and potentially life-threatening causes, especially while awaiting the results of genetic investigations.

Children require ongoing care within eye services where they will be seen regularly by ophthalmologists, orthoptists and optometrists to monitor the health and visual potential of the eye, and to ensure that any other amblyopic stimuli is minimised. In the UK, children and young people who are left with moderate reduction in their vision are referred to specialist advisory services for children with visual impairment in order to ensure that advice and support can be given to parents and to the educational services.

**Assessment and clinical examination/investigation.** An approach to assessment of children with cataract includes obtaining a history of the pregnancy and birth, with a focus on enquiring about maternal illness, drugs and medications in pregnancy, birth weight and neonatal events including jaundice treatment and clinical course. Subsequent history will be guided by the age of presentation, including current or past medical illness with particular attention to features of failure to thrive, developmental concerns and a thorough systems review. Family history and genogram should be obtained and investigations tailored to the history, age of presentation, gender and physical examination.

With a mobile and changing population, screening for congenital viral infections must be considered as there will be a small percentage of mothers who are not immune to rubella and thus at risk of becoming infected and passing on the infection to their unborn babies. Genetic testing for bilateral cases should be considered, whether through ophthalmic genetic specialists or clinical geneticists.

**Vision, development and supporting families.** Families of children with congenital cataract require...
information and support the first time they present to the eye clinic. Parents have concerns about their child’s prognosis and potential visual outcome, and how it will affect their future development and educational achievements. As children with sight impairment must optimise their vision, parents require guidance in the early years to know how to promote their child’s vision in order to maximise learning. Infants and children in the UK are referred to specialist teachers for children with visual impairment to provide crucial developmental guidance and support to families as the child moves through the toddler years into early nursery and statutory education. This support should go hand in hand with the paediatrician’s involvement, together with ophthalmology input with ongoing follow up in the children’s low-vision services.

Conclusion and future directions

Congenital cataract is a widely phenotypic heterogeneous disease with genetic and environmental causes to consider. Surgical management is the mainstay treatment for the cataract itself, but the clinical challenge is finding the cause. Many children presenting to health services with cataract with or without systemic features remain without a diagnosis. Genomic advances have accelerated the discovery of new cataract-causing mutations, and conditions associated with cataract continue to be identified. The ‘CAT-MAP’ database provides a comprehensive list of over 350 human and mouse genes and loci. This includes at least 16 human loci where the underlying causative gene remains unknown, as well as a list of cataract genes shown to cause a cataract phenotype in mice. Although there are genotype–phenotype discrepancies between mice and humans, these lists suggest there are still many genes to be discovered. Recent research is directed towards providing high-quality evidence of the clinical utility of genetic testing to facilitate its provision and successful integration into clinical practice. Accurate diagnosis of inherited cataract is crucial for patients and their families as it facilitates individualised genetic counselling. It enables the multidisciplinary team to best support optimum child development during a critical period, empower families with a diagnosis and help them to plan for the future.

Author note

Mariya Moosajee is also affiliated with The Francis Crick Institute, London, UK.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

This work was funded by the Wellcome Trust (Grant number 205174/Z/16/Z) and Leadiant Biosciences.

ORCID iDs

Suzannah J Bell https://orcid.org/0000-0002-3328-3698
Philippa Harding https://orcid.org/0000-0003-0763-3516

References

1. Chodick G, Sigurdson AJ, Kleinerman RA, et al. The risk of cataract among survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. Radiat Res 2016; 185: 366–374.
2. Rahi JS, Dezateux C and British Congenital Cataract Interest Group. Measuring and interpreting the incidence of congenital ocular anomalies: lessons from a national study of congenital cataract in the UK. Invest Ophthalmol Vis Sci 2001; 42: 1444–1448.
3. Patel A, Hayward JD, Tailor V, et al. The oculome panel test: next-generation sequencing to diagnose a diverse range of genetic developmental eye disorders. Ophthalmology 2019; 126: 888–907.
4. Yi J, Yun J, Li ZK, et al. Epidemiology and molecular genetics of congenital cataracts. Int J Ophthalmol 2011; 4: 422–432.
5. Musleh M, Hall G, Lloyd IC, et al. Diagnosing the cause of bilateral paediatric cataracts: comparison of standard testing with a next-generation sequencing approach. Eye (Lond) 2016; 30: 1175–1181.
6. Gillespie RL, Urquhart J, Anderson B, et al. Next-generation sequencing in the diagnosis of metabolic disease marked by pediatric cataract. Ophthalmology 2016; 123: 217–220.
7. Robert Barishak Y. Embryology of the eye and its adnexa. Basel: Karger Medical and Scientific Publishers, 2001.
8. Pichi F, Lembo A, Serafino M, et al. Genetics of congenital cataract. Dev Ophthalmol 2016; 57: 1–14.
9. Bassnett S, Shi Y and Vrensen GF. Biological glass: structural determinants of eye lens transparency. Philos Trans R Soc Lond B Biol Sci 2011; 366: 1250–1264.
10. Magli A, Carelli R, Forte R, et al. Congenital and developmental cataracts: focus on strabismus outcomes at long-term follow-up. *Semin Ophthalmol* 2017; 32: 358–362.

11. Hejtmancik JF. Congenital cataracts and their molecular genetics. *Semin Cell Dev Biol* 2008; 19: 134–149.

12. Shiels A and Hejtmancik JF. Genetic origins of cataract. *Arch Ophthalmol* 2007; 125: 165–173.

13. Khanna RC, Foster A, Krishnaiah S, et al. Visual outcomes of bilateral congenital and developmental cataracts in young children in south India and causes of poor outcome. *Indian J Ophthalmol* 2013; 61: 65–70.

14. Burdon KP, McKay JD, Sale MM, et al. Mutations in a novel gene, NHS, cause the pleiotropic effects of Nance–Horan syndrome, including severe congenital cataract, dental anomalies, and mental retardation. *Am J Hum Genet* 2003; 73: 1120–1130.

15. Ling C, Sui R, Yao F, et al. Whole exome sequencing identified a novel truncation mutation in the NHS gene associated with Nance–Horan syndrome. *BMC Med Genet* 2019; 20: 14.

16. Romano MT, Tafazzoli A, Mattner M, et al. Bi-allelic mutations in LSS, encoding lanosterol synthase, cause autosomal-recessive hypotrichosis simplex. *Am J Hum Genet* 2018; 103: 777–785.

17. Chen X and Liu L. Congenital cataract with LSS gene mutations: a new case report. *J Pediatr Endocrinol Metab* 2017; 30: 1231–1235.

18. Augusteyn RC. Alpha-crystallin: a review of its structure and function. *Clin Exp Optom* 2004; 87: 356–366.

19. Shiels A and Hejtmancik JF. Molecular genetics of cataract. *Prog Mol Biol Transl Sci* 2015; 134: 203–218.

20. Perng MD, Zhang Q and Quinlan RA. Insights into the beaded filament of the eye lens. *Exp Cell Res* 2007; 313: 2180–2188.

21. Nielsen PA, Baruch A, Shestopalov VI, et al. Lens connexins alpha3Cx46 and alpha8Cx50 interact with zonula occludens protein-1 (ZO-1). *Mol Biol Cell* 2003; 14: 2470–2481.

22. Beyer EC, Ebihara L and Berthoud VM. Connexin mutants and cataracts. *Front Pharmacol* 2013; 4: 43.

23. Berthoud VM and Ngezahayo A. Focus on lens connexins. *BMC Cell Biol* 2017; 18: 6.

24. Ding X, Wang B, Luo Y, et al. A novel mutation in the connexin 46 (GJA3) gene associated with congenital cataract in a Chinese pedigree. *Mol Vis* 2011; 17: 1343–1349.

25. Ge XL, Zhang Y, Wu Y, et al. Identification of a novel GJA8 (Cx50) point mutation causes human dominant congenital cataracts. *Sci Rep* 2014; 4: 4121.

26. Devi RR and Vijayalakshmi P. Novel mutations in GJA8 associated with autosomal dominant congenital cataract and microcornea. *Mol Vis* 2006; 12: 190–195.

27. Hansen L, Yao W, Eiberg H, et al. Genetic heterogeneity in microcornea- cataract: five novel mutations in CRYAA, CRYGD, and GJA8. *Invest Ophthalmol Vis Sci* 2007; 48: 3937–3944.

28. Shiels A and Hejtmancik JF. Mutations and mechanisms in congenital and age-related cataracts. *Exp Eye Res* 2017; 156: 95–102.

29. Agre P, Brown D and Nielsen S. Aquaporin water channels: unanswered questions and unresolved controversies. *Curr Opin Cell Biol* 1995; 7: 472–483.

30. Berry V, Francis P, Kaushal S, et al. Missense mutations in MIP underlie autosomal dominant ‘polymorphic’ and lamellar cataracts linked to 12q. *Nat Genet* 2000; 25: 15–17.

31. Kumari S, Gao J, Mathias RT, et al. Aquaporin 0 modulates lens gap junctions in the presence of lens-specific beaded filament proteins. *Invest Ophthalmol Vis Sci* 2017; 58: 6006–6019.

32. Louis CF, Hur KC, Galvan AC, et al. Identification of an 18,000-dalton protein in mammalian lens fiber cell membranes. *J Biol Chem* 1989; 264: 19967–19973.

33. Tenbroek E, Arneson M, Jarvis L, et al. The distribution of the fiber cell intrinsic membrane proteins MP20 and connexin46 in the bovine lens. *J Cell Sci* 1992; 103: 245–257.

34. Shiels A, King JM, Mackay DS, et al. Refractive defects and cataracts in mice lacking lens intrinsic membrane protein-2. *Invest Ophthalmol Vis Sci* 2007; 48: 500–508.

35. Shiels A, Bennett TM and Hejtmancik JF. CatMap: putting cataract on the map. *Invest Ophthalmol Vis Sci* 2007; 48: 500–508.

36. Irum B, Khan SY, Ali M, et al. Mutation in LIM2 is responsible for autosomal recessive congenital cataracts. *PLoS One* 2016; 11: e0162620.

37. Dave A, Martin S, Kumar R, et al. EphA2 mutations contribute to congenital cataract
through diverse mechanisms. *Mol Vis* 2016; 22: 18–30.

38. Dave A, Laurie K, Staffieri SE, et al. Mutations in the EPHA2 gene are a major contributor to inherited cataracts in South-Eastern Australia. *PLoS One* 2013; 8: e72518.

39. Park JE, Son AI, Hua R, et al. Human cataract mutations in EPHA2 SAM domain alter receptor stability and function. *PLoS One* 2012; 7: e36564.

40. Ansar M, Chung HL, Taylor RL, et al. Bi-allelic loss-of-function variants in DNMBP cause infantile cataracts. *Am J Hum Genet* 2018; 103: 568–578.

41. Gao M, Huang Y, Wang L, et al. HSF4 regulates lens fiber cell differentiation by activating p53 and its downstream regulators. *Cell Death Dis* 2017; 8: e3082.

42. Anand D, Agrawal SA, Slavotinek A, et al. Mutation update of transcription factor genes FOXE3, HSF4, MAF, and PITX3 causing cataracts and other developmental ocular defects. *Hum Mutat* 2018; 103: 568–578.

43. Ho HY, Chang KH, Nichols J, et al. Homeodomain protein Pitx3 maintains the mitotic activity of lens epithelial cells. *Mech Dev* 2009; 126: 18–29.

44. Cassidy L and Taylor D. Congenital cataract and multisystem disorders. *Eye (Lond)* 1999; 13: 464–473.

45. da Cunha RP and Moreira JB. Ocular findings in Down’s syndrome. *Am J Ophthalmol* 1996; 122: 236–244.

46. Bull MJ and Committee on Genetics. Health supervision for children with Down syndrome. *Pediatrics* 2011; 128: 393–406.

47. Roberts W, Zurada A, Zurada-Zieli NA, et al. Anatomy of trisomy 18. *Clin Anat* 2016; 29: 628–632.

48. Montjean R, Aoidi R, Desbois P, et al. OCRL-mutated fibroblasts from patients with Dent-2 disease exhibit INPP5B-independent phenotypic variability relatively to Lowe syndrome cells. *Hum Mol Genet* 2015; 24: 994–1006.

49. Bokenkamp A and Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. *Pediatr Nephrol* 2016; 31: 2201–2212.

50. Walker JL, Dixon J, Fenton CR, et al. Two new mutations in exon 3 of the NDP gene: S73X and S101F associated with severe and less severe ocular phenotype, respectively. *Hum Mutat* 1997; 9: 53–56.

51. Warburg M. Norrie’s disease: a congenital progressive oculo-acoustico-cerebral degeneration. *Acta Ophthalmol (Copenh)* 1966; (Suppl. 89): 1–47.

52. Coccia M, Brooks SP, Webb TR, et al. X-linked cataract and Nance–Horan syndrome are allelic disorders. *Hum Mol Genet* 2009; 18: 2643–2655.

53. Bixler D, Higgins M and Hartsfield J Jr. The Nance–Horan syndrome: a rare X-linked ocular-dental trait with expression in heterozygous females. *Clin Genet* 1984; 26: 30–35.

54. Li H, Yang L, Sun Z, et al. A novel small deletion in the NHS gene associated with Nance–Horan syndrome. *Sci Rep* 2018; 8: 2398.

55. Brooks SP, Coccia M, Tang HR, et al. The Nance–Horan syndrome protein encodes a functional WAVE homology domain (WHD) and is important for co-ordinating actin remodelling and maintaining cell morphology. *Hum Mol Genet* 2010; 19: 2421–2432.

56. Ikeda KS, Iwabe-Marchese C, Franca MC Jr, et al. Myotonic dystrophy type 1: frequency of ophthalmologic findings. *Arq Neuropsiquiatr* 2016; 74: 183–188.

57. Thornton CA. Myotonic dystrophy. *Neurol Clin* 2014; 32: 705–719, viii.

58. Ruggieri M, Pratico AD, Serra A, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. *Acta Otorhinolaryngol Ital* 2016; 36: 345–367.

59. Klouwer FC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical overview and management approach. *Orphanet J Rare Dis* 2015; 10: 151.

60. Distel B, Erdmann R, Gould SJ, et al. A unified nomenclature for peroxisome biogenesis factors. *J Cell Biol* 1996; 135: 1–3.

61. Khobta A and Epe B. Repair of oxidatively generated DNA damage in Cockayne syndrome. *Mech Ageing Dev* 2013; 134: 253–260.

62. Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. *J Biol Chem* 1991; 266: 7779–7783.

63. Nie S, Chen G, Cao X, et al. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. *Orphanet J Rare Dis* 2014; 9: 179.

64. Coelho AI, Rubio-Gozalbo ME, Vicente JB, et al. Sweet and sour: an update on classic
65. Khokhar SK, Pillay G, Dhull C, et al. Pediatric cataract. Indian J Ophthalmol 2017; 65: 1340–1349.

66. Demirbas D, Coelho AI, Rubio-Gozalbo ME, et al. Hereditary galactosemia. Metabolism 2018; 83: 188–196.

67. Foster A, Gilbert C and Rahi J. Epidemiology of cataract in childhood: a global perspective. J Cataract Refract Surg 1997; 23(Suppl. 1): 601–604.

68. Singh MP, Ram J, Kumar A, et al. Infectious agents in congenital cataract in a tertiary care referral center in North India. Diagn Microbiol Infect Dis 2016; 85: 477–481.

69. Dewan P and Gupta P. Burden of congenital rubella syndrome (CRS) in India: a systematic review. Indian Pediatr 2012; 49: 377–399.

70. de Jong EP, Vossen AC, Walther FJ, et al. How to use... neonatal TORCH testing. Arch Dis Child Educ Pract Ed 2013; 98: 93–98.

71. Khokhar S, Agarwal T, Kumar G, et al. Lenticular abnormalities in children. J Pediatr Ophthalmol Strabismus 2012; 49: 32–37.

72. Khokhar S, Gupta S, Yogi R, et al. Epidemiology and intermediate-term outcomes of open- and closed-globe injuries in traumatic childhood cataract. Eur J Ophthalmol 2014; 24: 124–130.

73. Gradin D and Yorston D. Intraocular lens implantation for traumatic cataract in children in East Africa. J Cataract Refract Surg 2001; 27: 2017–2025.

74. Rosenberg KD, Feuer WJ and Davis JL. Ocular complications of pediatric uveitis. Ophthalmology 2004; 111: 2299–2306.

75. Jobling AI and Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002; 85: 61–75.